H

Huakang Biomedical Holdings Co Ltd
HKEX:8622

Watchlist Manager
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Watchlist
Price: 0.164 HKD 1.86% Market Closed
Market Cap: 82.1m HKD
Have any thoughts about
Huakang Biomedical Holdings Co Ltd?
Write Note

Huakang Biomedical Holdings Co Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Huakang Biomedical Holdings Co Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
H
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Cash from Investing Activities
-ÂĄ1.2m
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
N/A
K
Kaisa Health Group Holdings Ltd
HKEX:876
Cash from Investing Activities
HK$47.2m
CAGR 3-Years
57%
CAGR 5-Years
N/A
CAGR 10-Years
8%
K
Kelfred Holdings Ltd
HKEX:1134
Cash from Investing Activities
-HK$16.6m
CAGR 3-Years
-47%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Arts Optical International Holdings Ltd
HKEX:1120
Cash from Investing Activities
-HK$111.3m
CAGR 3-Years
-13%
CAGR 5-Years
-31%
CAGR 10-Years
0%
O
OrbusNeich Medical Group Holdings Ltd
HKEX:6929
Cash from Investing Activities
-$52.3m
CAGR 3-Years
-67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Huakang Biomedical Holdings Co Ltd
Glance View

Market Cap
82.1m HKD
Industry
Health Care

Huakang Biomedical Holdings Co. Ltd. operates as a medical group company. The company employs 83 full-time employees The company went IPO on 2018-12-13. The IVD reagents include male fertility IVD reagents, Epstein-Barr virus antibody detection reagents ad parasite antibody detection reagents, among others. The male fertility IVD reagents include sperm function test products, accessory genital glands test products, anti-sperm antibody test products, as well as male reproductive tract infection test products, among others. In addition, the Company is also involved in the sale of auxiliary reproductive supplies and equipments, such as glass coverslips and sperm sample collection cups.

Intrinsic Value
0.085 HKD
Overvaluation 48%
Intrinsic Value
Price
H

See Also

What is Huakang Biomedical Holdings Co Ltd's Cash from Investing Activities?
Cash from Investing Activities
-1.2m CNY

Based on the financial report for Dec 31, 2023, Huakang Biomedical Holdings Co Ltd's Cash from Investing Activities amounts to -1.2m CNY.

What is Huakang Biomedical Holdings Co Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
14%

Over the last year, the Cash from Investing Activities growth was 81%. The average annual Cash from Investing Activities growth rates for Huakang Biomedical Holdings Co Ltd have been 16% over the past three years , 14% over the past five years .

Back to Top